Genasense panel questioned
Executive Summary
In a Sept. 26 letter to Oncology Office Director Richard Pazdur, Emil Freireich (M.D. Anderson) expresses concern that FDA's Oncologic Drugs Advisory Committee "was comprised of specialists who frankly admitted having no experience" with chronic lymphocytic leukemia for the panel's review of Genta's Genasense; the panel recommended against approval of oblimersen Sept. 6 (1"The Pink Sheet" Sept. 11, 2006, p. 3). Genasense's positive impacted on a composite response endpoint in pivotal trials merits approval, Freireich states...
You may also be interested in...
Genasense Accelerated Approval Not Supported Due To Failed Outcomes Data
Accelerated approval based on response rate is not appropriate for Genta's Genasense given the Bcl-2 inhibitor's failure to show a benefit on clinical outcomes in a randomized Phase III trial, FDA and members of its Oncologic Drugs Advisory Committee said during a Sept. 6 meeting
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.